[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351955-105":59,"doc-detail-351955-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncogenic-pik3ca-mutation-enhances-tumor-immunogenicity-through-the-irf1-nlrc5-mhc-i-axis-in-urothelial-carcinoma","Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma","","Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1–NLRC5–MHC-I axis in urothelial carcinoma. Immune checkpoint inhibitors improve outcomes in metastatic urothelial carcinoma, yet predictive biomarkers for response are not sufficiently defined. This study retrospectively evaluates 67 patients receiving ICIs using targeted 440-gene sequencing to link tumor mutational burden and genomic alterations with therapeutic benefit. Functional assays with urothelial carcinoma cell co-cultures, gene knockdown/overexpression, and CRISPR/Cas9 murine models show that PIK3CA-driven IRF1-NLRC5-MHC-I signaling increases antigen presentation, cytokine output, and CD8+ cytotoxicity, supporting PIK3CA as a mechanistic immunoregulatory determinant of PD-L1 blockade response.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncogenic-pik3ca-mutation-enhances-tumor-immunogenicity-through-the-irf1-nlrc5-mhc-i-axis-in-urothelial-carcinoma/351955/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncogenic-pik3ca-mutation-enhances-tumor-immunogenicity-through-the-irf1-nlrc5-mhc-i-axis-in-urothelial-carcinoma/351955.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical problem does this study address in metastatic urothelial carcinoma?","Question",{"text":112,"@type":113},"It addresses the lack of reliable predictive biomarkers for response to immune checkpoint inhibitors in metastatic urothelial carcinoma, where current markers like PD-L1 and tumor mutational burden are limited or inconsistent.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the association between PIK3CA and ICI response investigated?",{"text":117,"@type":113},"The study retrospectively analyzed 67 patients treated with ICIs, performed targeted next-generation sequencing with a 440-gene panel, and evaluated tumor mutational burden, genomic alterations, and clinical outcomes to identify response-linked biomarkers.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism connects oncogenic PIK3CA to improved immunogenicity and PD-L1 blockade efficacy?",{"text":121,"@type":113},"PIK3CA mutations activate the IRF1-NLRC5-MHC-I axis, increasing antigen presentation (including HLA-A and B2M expression), which enhances CD8+ T-cell-mediated cytotoxicity; functional and in vivo experiments show loss of PIK3CA reduces responses to anti-PD-L1 therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351955,1790153102,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Original research  \n OncogenicPIK3CA mutation enhances  \ntumor immunogenicity through the IRF1–NLRC5–MHC-I axis inurothelial carcinoma  \nTo cite: Su Y-L, Huang S-Y, Kuo C-W, et al. Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1–NLRC5–MHC-I axis inurothelial carcinoma. Journal for ImmunoTherapy of Cancer 2026;14:e014770 . doi:10 . 1136/ jitc-2026-014770  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2026-014770](jitc-2026-014770)) .  \nAccepted 15 June 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Chih-Yen Chien;  \n[cychein3965@adm.cgmh.org.tw](cychein3965@adm.cgmh.org.tw)  \nDr Hsuan-Ying Huang; [a120600310@yahoo.com](a120600310@yahoo.com)  \nDr Chia-Ling Wu;  \n[jalinwu@actgenomics.com](jalinwu@actgenomics.com)  \nYu-Li Su  ,1,2 Shih-Yu Huang,2 Chung-Wen Kuo,2 Ling-Yi Xiao,3 Chang-Ting Lin,2 Yi-Hua Chen,2 Li-Chung Chang,2 Ming-Chun Kuo,2 Chia-Che Wu,2 Jei-Ming Peng,4 Chia-Ling Wu  ,5 Hsuan-Ying Huang,6,7 Chih-Yen Chien1,8  \nABSTRACT  \nBackground Immune checkpoint inhibitors (ICIs) have significantly improved overall survival in metastatic urothelial carcinoma (mUC) . However, predictive biomarkers for therapeutic response remain insufficiently defined. Although some genomic alterations have been implicated in modulating tumor immunogenicity and ICI sensitivity in other cancers, evidence in mUC remains limited and warrants further investigation.  \nMethods We retrospectively analyzed 67 patients with mUC treated with ICIs and performed targeted nextgeneration sequencing using a 440-gene cancer panel. Tumor mutational burden (TMB), genomic alterations, and clinical outcomes were evaluated to identify biomarkers associated with ICI response. Functional studies were conducted using urothelial carcinoma cell lines co-cultured with peripheral blood mononuclear cells (PBMCs) with or without anti-programmed deathligand 1 (PD-L1) treatment to evaluate tumor viability, cytokine responses, and antigen presentation. Gene knockdown and overexpression experiments, quantitative PCR, immunofluorescence, and western blotting were used to assess cytokine production, antigen presentation machinery components, and major histocompatibility complex (MHC) class I expression. In vivo validation was performed using CRISPR/Cas9-mediated knockout syngeneic murine models treated with anti-PD-L1 to assess tumor growth, immune infiltration, and therapeutic response through immunohistochemistry and flow cytometry.  \nResults Responders to ICI monotherapy exhibited significantly higher TMB and enriched mutations in PIK3CA, ADAMTSL1, NSD1, and PRKDC. Hotspot PIK3CA mutations correlated with elevated TMB across multiple TCGA pan-cancer, breast and colorectal cohorts. Functionally, PIK3CA-mutant tumor cells demonstrated  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Immune checkpoint inhibitors are an established treatment for metastatic urothelial carcinoma; however, only a subset of patients derive durable clinical benefit. Currently used biomarkers, such as programmed death-ligand 1 (PD-L1) expression and tumor mutational burden, show limited and inconsistent predictive value. Moreover, the relationship between specific tumor genomic alterations and tumor immunogenicity in urothelial carcinoma remains poorly characterized.\u003Cbr>WHAT THIS STUDY ADDS |\n| ⇒ This study identifies PIK3CA mutation as a previously unrecognized immunoregulatory determinant of response to PD-L1 blockade in urothelial carcinoma. We demonstrate that oncogenic PIK3CA activates the IRF1-NLRC5-MHC class I pathway, enhancing antigen presentation and CD8+ T-cell-mediated cytotoxicity. These findings establish a direct mechanistic li","cbCaisfniAIJJGSk","https://ap.wps.com/l/cbCaisfniAIJJGSk","pdf",16681004,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What clinical problem does this study address in metastatic urothelial carcinoma?\",\"answer\":\"It addresses the lack of reliable predictive biomarkers for response to immune checkpoint inhibitors in metastatic urothelial carcinoma, where current markers like PD-L1 and tumor mutational burden are limited or inconsistent.\"},{\"question\":\"How was the association between PIK3CA and ICI response investigated?\",\"answer\":\"The study retrospectively analyzed 67 patients treated with ICIs, performed targeted next-generation sequencing with a 440-gene panel, and evaluated tumor mutational burden, genomic alterations, and clinical outcomes to identify response-linked biomarkers.\"},{\"question\":\"What mechanism connects oncogenic PIK3CA to improved immunogenicity and PD-L1 blockade efficacy?\",\"answer\":\"PIK3CA mutations activate the IRF1-NLRC5-MHC-I axis, increasing antigen presentation (including HLA-A and B2M expression), which enhances CD8+ T-cell-mediated cytotoxicity; functional and in vivo experiments show loss of PIK3CA reduces responses to anti-PD-L1 therapy.\"}]","Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma | PDF",1790096597,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/551b1245547be38f81bc0ecfdb072cf5.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/931673c958ca31fa3a750aae0ccbca7d.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4911731e87e2345c7176576223c8f3ff.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d26f05249b0266ab443e898f99809bd0.webp",980,1306]